Baradaran Ghavami S Haghayegh, Shahrokh S Habnam, Hossein-Khannazer Nikoo, Shpichka Anastasia, Asadzadeh Aghdaei Hamid, Timashev Peter, Vosough Massoud
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cell J. 2020 Jul;22(Suppl 1):151-154. doi: 10.22074/cellj.2020.7603. Epub 2020 Jul 18.
Inflammatory bowel diseases (IBDs) are chronic disorders of the gastrointestinal tract. The goal of IBD treatment is to reduce the inflammation period and induce long-term remission. Use of anti-inflammatory drugs including corticosteroids, immunosuppressants and biologicals, is often the first step in the treatment of IBD. Therefore, IBD patients in pandemic of infectious diseases are considered a high-risk group. The public believes that IBD patients are at a higher risk in the current coronavirus 2 pandemic. Nevertheless, these patients may experience mild or moderate complications compared to healthy people. This might be because of particular anti-TNF-α treatment or any immunosuppressant that IBD patients receive. Moreover, these patients might be silent carrier for the virus.
炎症性肠病（IBD）是胃肠道的慢性疾病。IBD治疗的目标是缩短炎症期并诱导长期缓解。使用包括皮质类固醇、免疫抑制剂和生物制剂在内的抗炎药物通常是IBD治疗的第一步。因此，在传染病大流行期间，IBD患者被视为高危人群。公众认为IBD患者在当前的新型冠状病毒2大流行中风险更高。然而，与健康人相比，这些患者可能会出现轻度或中度并发症。这可能是由于IBD患者接受的特殊抗TNF-α治疗或任何免疫抑制剂。此外，这些患者可能是病毒的无症状携带者。
